Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 658, P. 124192 - 124192

Published: May 3, 2024

Ocular delivery is the most challenging aspect in field of pharmaceutical research. The major hurdle for controlled drugs to eye includes physiological static barriers such as complex layers cornea, sclera and retina which restrict drug from permeating into anterior posterior segments eye. Recent years have witnessed inventions conventional nanocarrier shown considerable enhancement delivering small large molecules across dynamic challenges associated with systems include limited contact time inadequate ocular bioavailability resulting solution drainage, tear turnover, dilution or lacrimation. To this end, various bioactive-based nanosized carriers including liposomes, ethosomes, niosomes, dendrimer, nanogel, nanofibers, lenses, nanoprobes, selenium nanobells, nanosponge, polymeric micelles, silver nanoparticles, gold nanoparticles among others been developed circumvent limitations dosage forms. These nanocarriers achieve enhanced permeation retention prolong release tissue due their better adherence. surface charge size (10–1000 nm) are important key factors overcome barriers. Various deliver active therapeutic timolol maleate, ampicillin, natamycin, voriconazole, cyclosporine A, dexamethasone, moxifloxacin, fluconazole treatment diseases. Taken together, a nutshell, book chapter provides comprehensive perspective on numerous facets special focus bioactive nanocarrier-based approaches, difficulties constraints involved fabrication nanocarriers. This also detailed invention applications ophthalmic therapeutics.

Language: Английский

Evaluation of the Ocular Safety of Hollow Mesoporous Organosilica Nanoparticles with Different Tetrasulfur Bond Content

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 7123 - 7136

Published: July 1, 2024

Drug therapy for eye diseases has been limited by multiple protective mechanisms of the eye, which can be improved using well-designed drug delivery systems. Mesoporous silica nanoparticles (MSNs) had used in many studies as carriers therapeutic agents ocular treatment. However, no have focused on biosafety. Considering that MSNs containing tetrasulfur bonds unique advantages and drawn increasing attention systems, it is necessary to explore biosafety before their widespread application ophthalmic carriers.

Language: Английский